内容

目次

I: Pharmaceutical biotechnology for target validation Chapter 1: GENERATION OF TRANSGENIC ANIMALS Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS II: Target validation for biopharmaceutical drug discovery Chapter 3: CETUXIMAB (ERBITUX®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION III: Validating targets of small molecule approaches Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY INDEX